Only 57 percent of healthcare organizations use data to make business decisions, despite 90 percent of healthcare leaders agreeing that access to quality data is critical to organizational performance, according to a new report by Arcadia.
The Current State of Healthcare Analytics Report insights come from a pulse survey on the current state of healthcare analytics platforms conducted by the Healthcare Information and Management Systems Society (HIMSS) and Arcadia.
Key Findings
A growing demand for healthcare data: Approximately 30% of the world’s data volume is generated by the healthcare industry, with the compound annual growth rate of healthcare data forecasted to reach 36% by 2025.2 To better managed and act on data, a quarter of healthcare leaders have plans to integrate care team communications and population health management solutions within the next 12 months.1
Challenges hinder technological advancement: The most significant barrier healthcare leaders face when investing in or upgrading an analytics platform is resources. 71% cite competing priorities, 58% point to staffing challenges, and 47% said they don’t have sufficient budget.1
Views vary on artificial intelligence (AI): Nearly 30% of healthcare leaders said they’ve already implemented AI with roughly 60% planning to implement such technology in the next 12-24 months or more.1 A small percentage (13%) don’t plan to implement AI at all.1 C-suite leaders are more likely to have plans to implement AI within the next 12 months (30%) compared to those in other leadership positions (7%).1
Clinical Decision Support: Larger organizations are more likely to implement clinical decision tools within the next 12 months
Standardizing Templates for Medical Conditions: Multi-hospital systems are less likely to standardize templates for medical conditions within the next 12 months.
Epic AI Adoption: Epic users are more likely to have already implemented AI/ML (29%) and the majority plan to implement AI/ML within the next 12-24 months.
Pfizer and OPKO’s Ngenla will be available in America, having already been approved in 40 other markets. Source: Shutterstock/ShU studio. Pfizer has announced that the
EQS-News: AiCuris Anti-infective Cures AG / Key word(s): Miscellaneous AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS®
The 50-mg dose of the investigational drug brilaroxazine significantly reduced symptoms of schizophrenia in adults within 4 weeks in the phase III RECOVER trial, developer
Only Half of Healthcare Organizations’ Data is Used to Make Decisions
by Fred Pennic Leave a Comment
What You Should Know:
Key Findings
Pfizer’s Ngenla finally secures FDA approval following a rocky road to market – Pharmaceutical Technology
Pfizer and OPKO’s Ngenla will be available in America, having already been approved in 40 other markets. Source: Shutterstock/ShU studio. Pfizer has announced that the
AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS® for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients – Biotech Investments
EQS-News: AiCuris Anti-infective Cures AG / Key word(s): Miscellaneous AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS®
Phase III Win in Schizophrenia; Bipolar Blood Test; How Do Psychedelics Work?
The 50-mg dose of the investigational drug brilaroxazine significantly reduced symptoms of schizophrenia in adults within 4 weeks in the phase III RECOVER trial, developer